ArticleFrontiers in endocrinology2025
Joint impact of serum urate, renal function, and genetic susceptibility on coronary heart disease and ischemic stroke risk: a population-based study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between serum urate and cardiovascular disease (CVD) is well-established, but its interplay with renal function and genetic susceptibility remains less clear. The study aimed to investigate the individual and joint associations of serum urate, renal function, and genetic risk with incident CVD. Methods: The study included 383,390 participants from the UK Biobank, initially free of CVDs at baseline. Serum urate levels and kidney damage markers were obtained. We used a new approach to construct an estimated glomerular filtration rate, and incorporate albumin-creatinine ratio to assess renal function. Genetic risk scores for CHD and IS were calculated. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox models. Results: Over a median 13.24-year follow-up, 35,932 CVD events were documented, including 30,025 CHD and 5,524 IS cases. Each standard deviation increase in urate was associated with HRs (95% CIs) of 1.09 (1.08, 1.11) for CVD, 1.08 (1.08, 1.11) for CHD, and 1.12 (1.08, 1.15) for IS. Elevated urate, in combination with impaired renal function or higher genetic risk, further increased CVDs risk. Participants with poor renal function and the highest tertile urate had approximately three times the risk of CVDs compared to those with normal kidney function and the lowest urate tertile. Similar trends were observed for the joint impact of genetic susceptibility and urate. Conclusions: Our findings underscore the importance of managing urate levels in individuals with renal impairment or genetic susceptibility in the prevention of CVDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.